KRAS and pachyonychia congenita: Gene invalidation therapy for PC mainly focuses on targeting oncogenes such as KRAS, as well as new methods of directly targeting non-coding RNAs (ncRNAs).It is evident that the GTPase mutant form of KRAS exerts a pivotal role in the development of PC [162].